The Proton Pump Inhibitors Market Is Estimated To Increase At A CAGR Of 4.5 Percent During The Forecast Period 2021-2026

Proton pump inhibitors are a class of drugs that limit gastric acid output in the stomach's linings. They inhibit an enzyme in the gastric system that actively transfers gastric acid in hydrogen–potassium adenosine triphosphate from parietal cells to the gastrointestinal lumen (proton pump). Gastroesophageal reflux disease (GERD), peptic ulcers, dyspepsia, gastritis, and other gastrointestinal problems are treated with proton pump inhibitors. The medications are used orally and come in the shape of capsules and pills. Because they have fewer adverse effects, proton pump inhibitors are among the most commonly prescribed drugs.

The Proton Pump Inhibitors Market was worth USD 2,750 million in 2020, and it is expected to grow to USD 3,585 million in 2026, with a CAGR of almost 4.5 percent between 2021 and 2026. According to numerous studies, proton pump inhibitors have been linked to an increased risk of COVID-19 among individuals who use them. For example, in 2020, the American Journal of Gastroenterology published a study in which over 53,000 persons taking proton pump inhibitors took part, with 3,386 of them reporting that they had tested positive for COVID-19. This factor is predicted to impact market growth because patients on PPI therapy are urged to take less medicine and avoid taking these medications unless necessary. As a result, COVID-19 is having a detrimental impact on this market.

The proton pump inhibitors market is being driven by increased acceptance of innovative medication delivery technologies and the rising prevalence of peptic ulcers and other gastrointestinal ailments. Consumers in remote areas choose ordinary antacids to treat ulcers and gastrointestinal diseases, limiting the proton pump inhibitors market. In addition, the growing usage of generic pharmaceuticals in the proton pump inhibitors industry may stifle market growth. The proton pump inhibitors industry can always benefit from increased consumer acceptance of newer drug delivery technologies and the introduction of new medicines.

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa make up the proton pump inhibitors market. North America held the largest market share, owing to an increase in gastrointestinal illnesses in the region and the continual introduction of new products. However, there are many gastrointestinal medication items on the market in the Asia Pacific, and there is a significant patient pool with gastrointestinal issues. This may result in a demand for curative pharmaceuticals, which is expected to propel the proton pump inhibitors market in the region to new heights.

AstraZeneca PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals India Pvt. Ltd, Santarus, Inc Wyeth, LLC, Janssen Pharmaceutica, Takeda Pharmaceutical Company Limited, Sanofi S.A, and Aurobindo Pharma are the major key players of Proton Pump Inhibitors Market.